Skip to main content
Log in

Delayed response and survival from NovoTTF-100A in recurrent GBM

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript


We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2


  1. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.

    Article  PubMed  CAS  Google Scholar 

  2. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002;58:1109–12.

    Article  PubMed  CAS  Google Scholar 

  3. Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–5.

    Article  PubMed  Google Scholar 

  4. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.

    Article  PubMed  Google Scholar 

  5. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir. 2009;151:1349–58.

    Article  PubMed  Google Scholar 

  6. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012.

  7. Louis DN, International Agency for Research on Cancer, World Health Organization, Deutsches Krebsforschungszentrum Heidelberg. WHO classification of tumours of the central nervous system. Lyon Geneva, Switzerland: International Agency for Research on Cancer, Distributed by WHO Press, World Health Organization; 2007. p. 309.

  8. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.

    Article  PubMed  Google Scholar 

Download references


Authors received fund from Novocure clinical trial sponsorship.

Conflict of interest


Author information

Authors and Affiliations


Corresponding author

Correspondence to J. Lee Villano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villano, J.L., Williams, L.E., Watson, K.S. et al. Delayed response and survival from NovoTTF-100A in recurrent GBM. Med Oncol 30, 338 (2013).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: